<DOC>
	<DOC>NCT00836875</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.</brief_summary>
	<brief_title>A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Immunocompromised with clinically compatible illness. Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a modified version of the revised EORTC/MSG consensus definitions). Diagnosis of infection due to Scedosporium or Fusarium species. Male and female from 2 to 17 years of age. Females with childbearing potential must have negative pregnancy test and be using appropriate contraception. Allergy or hypersensitivity to the azole drugs. Female subjects who are pregnant or lactating. Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection. Received within 24 hours prior to enrollment drugs that may cause QT interval prolongation. Significant liver, kidney or heart dysfunction. Not expected to survive for at least 5 days.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pediatrics voriconazole invasive fungal infection invasive aspergillosis immunocompromized</keyword>
</DOC>